These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 338927)

  • 21. Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens.
    McMahon RE; Cline JC; Thompson CZ
    Cancer Res; 1979 Mar; 39(3):682-93. PubMed ID: 371791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
    Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR
    Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
    Chang TK; Waxman DJ
    Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutagenicity of organophosphorus compounds in bacteria and Drosophila.
    Hanna PJ; Dyer KF
    Mutat Res; 1975 Jun; 28(3):405-20. PubMed ID: 806014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutagenic activity of acrolein in S. typhimurium and E. coli.
    Parent RA; Caravello HE; San RH
    J Appl Toxicol; 1996; 16(2):103-8. PubMed ID: 8935782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of subcellular fractions of mammalian testes on the mutagenic activity of nitrofurans toward Escherichia coli; presence of a co-mutagen-like factor.
    Maier P; Philpot RM; Mohn GR; Malling HV
    Mutat Res; 1979 Dec; 63(2):233-43. PubMed ID: 118378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alkylating properties of phosphoramide mustard.
    Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
    Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of specific base-pair substitutions in E. coli trpA mutants by chloroethylene oxide, a carcinogenic vinyl chloride metabolite.
    Barbin A; Besson F; Perrard MH; Béréziat JC; Kaldor J; Michel G; Bartsch H
    Mutat Res; 1985; 152(2-3):147-56. PubMed ID: 3906388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mutagenic action of nitroso compounds on Escherichia coli cells].
    Pogodina ON
    Genetika; 1978; 14(12):2113-8. PubMed ID: 369946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of bacterial metabolism in transformation of non-mutagenic compounds into mutagens. I. Participation of Escherichia coli nitroreductase in creation of mutagens from non-mutagenic new pesticides].
    Szarapińska-Kwaszewska J; Mikucki J
    Med Dosw Mikrobiol; 1992; 44(1-2):29-34. PubMed ID: 1297031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutagenicity of nitrofuran drugs in bacterial systems.
    Ebringer L; Bencová M
    Folia Microbiol (Praha); 1980; 25(5):388-96. PubMed ID: 7000641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
    Kohn FR; Sladek NE
    Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible role of acrolein in 4-hydroperoxycyclophosphamide-induced cell damage in vitro.
    Blomgren H; Hallström M
    Methods Find Exp Clin Pharmacol; 1991; 13(1):11-4. PubMed ID: 1908032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutagenic activities of cyclophosphamide (NSC-26271) and its main metabolites in Salmonella typhimurium, human peripheral lymphocytes and Chinese hamster ovary cells.
    Winckler K; Obe G; Madle S; Nau H
    Mutat Res; 1984 Oct; 129(1):47-55. PubMed ID: 6387470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro.
    Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP
    J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of in vitro immunosuppression by hepatocyte-generated cyclophosphamide metabolites and 4-hydroperoxycyclophosphamide.
    Kawabata TT; Chapman MY; Kim DH; Stevens WD; Holsapple MP
    Biochem Pharmacol; 1990 Sep; 40(5):927-35. PubMed ID: 2117927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutagenicity of isomeric alkanediazotates, precursors for ultimate alkylating species of carcinogenic N-nitroso compounds.
    Ukawa-Ishikawa S; Sawada A; Kasuya K; Mochizuki M
    Mutat Res; 1998 Jan; 412(1):99-107. PubMed ID: 9508369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutagenic properties of allylic and alpha, beta-unsaturated compounds: consideration of alkylating mechanisms.
    Eder E; Henschler D; Neudecker T
    Xenobiotica; 1982 Dec; 12(12):831-48. PubMed ID: 6763406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of the control of mutagenic metabolites derived from cyclophosphamide and ifosfamide by stimulation of protein kinase A.
    Oesch-Bartlomowicz B; Vogel S; Arens HJ; Oesch F
    Mutat Res; 1990 Oct; 232(2):305-12. PubMed ID: 2170835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.